|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Acute lower gastrointestinal bleeding from a dieulafoy lesion proximal to the anorectal junction post-orthotopic liver transplant显示文摘A 67-year-old woman underwent an orthotopic liver transplantation for end stage liver disease secondary to chronic autoimmune hepatitis. She developed sudden massive hematochezia on post-operative day 23 with hemodynamic compromise. The source of hemorrhage was found at colonoscopy after careful irrigation and inspection to be a dieulafoy lesion situated just proximal to the anorectal junction. Hemostasis was achieved with epinephrine injection and thermal coagulation. | Wichian Apiratpracha Jin Kee Ho James J Powell Eric M Yoshida | 2006 | World Journal of Gastroenterology2006，12，46： | 12 |
| 2 | Response to endoscopic therapy for biliary anastomotic strictures in deceased versus living donor liver transplantation显示文摘BACKGROUND:Endoscopic therapy has been successful in the management of biliary complications after both deceased donor liver transplantation(DDLT) and living donor liver transplantation(LDLT).LDLT is thought to be associated with higher rates of biliary complications,but there are few studies comparing the success of endoscopic management of anastomotic strictures between the two groups.This study aims to compare our experience in the endoscopic management of anastomotic strictures in DDLT versus LDLT.METHODS:This is a retrospective database review of all liver transplant patients undergoing endoscopic retrograde cholangiopancreatography(ERCP) after liver transplantation.The frequency of anastomotic stricture and the time to develop and to resolve anastomotic stricture were compared between DDLT and LDLT.The response of anastomotic stricture to endoscopic therapy was also analyzed.RESULTS:A total of 362 patients underwent liver transplantation between 2003 and 2011,with 125 requiring ERCP to manage biliary complications.Thirty-three(9.9%) cases of DDLT and 8(27.6%) of LDLT(P=0.01) were found to have anastomotic stricture.When comparing DDLT and LDLT,there was no difference in the mean time to the development of anastomotic strictures(98±17 vs 172±65 days,P=0.11),likelihood of response to ERCP [22(66.7%) vs 6(75.0%),P=0.69],mean time to the resolution of anastomotic strictures(268±77 vs 125±37 days,P=0.34),and the number of ERCPs required to achieve resolution(3.9±0.4 vs 4.7±0.9,P=0.38).CONCLUSIONS:Endoscopic therapy is effective in the majority of biliary complications relating to liver transplantation.Anastomotic strictures occur more frequently in LDLT compared with DDLT,with equivalent endoscopic treatment response and outcomes for both groups. | Calvin HY Chan Fergal Donnellan Michael F Byrne Alan Coss Mazhar Haque Holly Wiesenger Charles H Scudamore Urs P Steinbrecher Alan A Weiss Eric M Yoshida | 2013 | Hepatobiliary & Pancreatic Diseases International2013，12，5： | 7 |
| 3 | Hepatoid adenocarcinoma of the colon in a patient with inflammatory bowel disease显示文摘A case is presented of a 36-year-old male with primary sclerosing cholangitis-associated inflammatory bowel disease(PSC-IBD) and two synchronous stage 1 adenocarcinomata of the colon,who was initially treated with a subtotal colectomy with ileostomy.One year later,the patient presented with extensive intra-abdominal lymphadenopathy and peritoneal carcinomatosis,as well as a markedly elevated serum level of alpha-fetoprotein(AFP).Fine needle aspiration biopsy of a porta hepatis lymph node revealed a metastatic hepatoid adenocarcinoma.Subsequent review of the previous colectomy specimen showed that one of the previously identified adenocarcinomata had features suggestive of a hepatoid colonic adenocarcinoma.The patient was subsequently treated with a cytotoxic regimen of FOLFOX(oxaliplatin,leucovorin,5-fluorouracil) and bevacizumab,with stable results being achieved after six months.This case presents the first known report of PSC-IBD associated with synchronous typical and hepatoid adenocarcinomata of the colon and highlights the importance of considering hepatoid adenocarcinoma as a differential diagnosis in patients with an increasing serum AFP level. | Yuanyuan Chen David F Schaeffer Eric M Yoshida | 2014 | World Journal of Gastroenterology2014，20，35： | 6 |
| 4 | Recurrent ectopic pancreatitis of the jejunum and mesentery over a 30-year period显示文摘BACKGROUND:Ectopic pancreas is defined as pancreatic tissue found outside its usual anatomical position,with no ductal or vascular communication with the native pancreas. We describe a case of ectopic pancreas of the small bowel and mesentery causing recurrent episodes of pancreatitis, initially suspected on computed tomography(CT)and magnetic resonance cholangiopancreatography(MRCP),and confirmed on histological review of the resection. METHODS:A 67-year-old woman presented with clinical symptoms and biochemical evidence of pancreatitis.She had similar episodes over the past 30 years with unrevealing investigations,and was concluded to have idiopathic pancreatitis. She underwent CT and MRCP,with findings suggestive of ectopic pancreas,a diagnosis confirmed on histology of the resection. RESULTS:MRCP identified a mass in the proximal small bowel mesentery isointense to the native pancreas,with a small duct draining into a proximal jejunal loop.The resected specimen consisted of normal parenchyma with lobulated acinar tissue with scattered islets of Langerhans,an occasional ductular structure,and admixed areas of adipose tissue.The patient remained asymptomatic with normal biochemistry six months post-operatively. CONCLUSION:In an individual with abdominal pain,elevated serum amylase/lipase,but imaging findings of a normal native pancreas,ectopic pancreatitis should be considered,and can be evaluated by CT and MRCP. | John CT Wong Charlotte Robinson Edward C Jones Alison Harris Charles Zwirewich Robert Wakefield Richard K Simons Eric M Yoshida | 2011 | Hepatobiliary & Pancreatic Diseases International2011，10，2： | 4 |
| 5 | Parvovirus B19 induced hepatic failure in an adult requiring liver transplantation显示文摘Parvovirus B19 induced acute hepatitis and hepatic failure have been previously reported, mainly in children. Very few cases of parvovirus induced hepatic failure have been reported in adults and fewer still have required liver transplantation. We report the case of a 55-year-old immunocompetent woman who developed fulminant hepatic failure after acute infection with Parvovirus B19 who subsequently underwent orthotopic liver transplantation. This is believed to be the first reported case in the literature in which an adult patient with fulminant hepatic failure associated with acute parvovirus B19 infection and without hematologic abnormalities has been identified prior to undergoing liver transplantation. This case suggests that Parvovirus B19 induced liver disease can affect adults, can occur in the absence of hematologic abnormalities and can be severe enough to require liver transplantation. | Darin S Krygier Urs P Steinbrecher Martin Petric Siegfried R Erb Stephen W Chung Charles H Scudamore Andrzej K Buczkowski Eric M Yoshida | 2009 | World Journal of Gastroenterology2009，15，32： | 3 |
| 6 | Acute sensorineural hearing loss associated with peginterferon and ribavirin combination therapy during hepatitis C treatment: Outcome after resumption of therapy显示文摘Peginterferon and ribavirin combination therapy for the treatment of hepatitis C virus (HCV) is well known to be associated with significant adverse effects. Sensorineural hearing loss, that in most cases is unilateral, has been reported as a consequence of therapy with both non-pegylated and pegylated interferon (pegIFN) but is not a well-known adverse effect. We report a 45-year-old Caucasian woman who developed acute sensorineural hearing loss 2 mo after starting therapy with pegIFN-α 2b and ribavirin for the treatment of chronic HCV, genotype 1a. She did not report the hearing loss to the hepatitis clinic until L mo,later whereupon therapy was promptly discontinued.Although her serum alanine aminotransferase (ALT)normalized and her HCV-RNA became undetectable after 12 wk of pegIFN and ribavirin therapy, after discontinuation,her HCV-RNA became detectable with significant elevations of serum ALT. Four months after initial discontinuation,the patient re-commenced pegIFN and ribavirin combination therapy. After 44 of 48 wk of therapy, the patient's liver biochemistry has normalized and the HCV-RNA is undetectable. She has not developed worsening of her hearing loss and hearing on the left-side is unaffected.Both patients and physicians should be aware that sensorineural hearing loss may occur with pegIFN therapy.Our experience suggests that re-institution of therapy is not always associated with further hearing impairment. | Victor K Wong Cindy Cheong-Lee Jo-Ann E Ford Eric M Yoshida | 2005 | World Journal of Gastroenterology2005，11，34： | 2 |
| 7 | Efficacy and safety of semaglutide in non-alcoholic fatty liver disease显示文摘BACKGROUND Non-alcoholic fatty liver disease(NAFLD)is the leading cause of chronic liver disease.The prevalence and disease burden of NAFLD are projected to exponentially increase resulting in significant healthcare expenditures and lower healthrelated quality of life.To date,there are no approved pharmacotherapies for NAFLD or non-alcoholic steatohepatitis(NASH).Semaglutide has glycemic and weight loss benefits that may be advantageous for patients with NAFLD.AIM To investigate the efficacy and safety of semaglutide in patients with NAFLD.METHODS MEDLINE,CENTRAL,and EMBASE were searched from inception to May 1,2023,to identify eligible randomized controlled trials(RCTs).Meta-analysis was performed using random effects model expressing continuous outcomes as mean differences(MD)or standardized MDs(SMD),and dichotomous outcomes as odds ratios(OR)with 95%confidence intervals(CI).Statistical heterogeneity was assessed using the Cochran’s Q test and I2 statistic.RESULTS Three RCTs involving 458 patients were included.Semaglutide increased the likelihood of NASH resolution(OR:3.18,95%CI:1.70,5.95;P<0.001),improvement in steatosis(OR:2.83,95%CI:1.19,6.71;P=0.03),lobular inflammation(OR:1.81,95%CI:1.11,2.96;P=0.02),and hepatocellular ballooning(OR:2.92,95%CI:1.83,4.65;P<0.001),but not fibrosis stage(OR:0.71,95%CI:0.15,3.41;P=0.67).Radiologically,semaglutide reduced liver stiffness(SMD:-0.48,95%CI:-0.86,-0.11;P=0.01)and steatosis(MD:-4.96%,95%CI:-9.92,0.01;P=0.05).It also reduced alanine aminotransferase(MD:-14.06 U/L,95%CI:-22.06,-6.07;P<0.001)and aspartate aminotransferase(MD:-11.44 U/L,95%CI:-17.23,-5.65;P<0.001).Semaglutide led to improved cardiometabolic outcomes,including decreased HgA1c(MD:-0.77%,95%CI:-1.18,-0.37;P<0.001)and weight loss(MD:-6.53 kg,95%CI:-11.21,-1.85;P=0.006),but increased the occurrence of GIrelated side effects(OR:3.72,95%CI:1.68,8.23;P=0.001).Overall risk of serious adverse events was similar compared to placebo(OR:1.40,95%CI:0.75,2.62;P<0.29).CONCLUSION Semaglutide is effective in the treatment of NAFLD while maintaining a well-tolerated safety profile.Future studies are required to evaluate its effects on fibrosis regression and different phases of NAFLD. | Kai Zhu Rohan Kakkar Daljeet Chahal Eric M Yoshida Trana Hussaini | 2023 | World Journal of Gastroenterology2023，29，37： | 2 |
| 8 | Biomarkers for hepatocellular cancer显示文摘Hepatocellular carcinoma(HCC)is the third leading cause of cancer-related deaths worldwide.If diagnosed early,curative treatment options such as surgical resection,loco-regional therapies,and liver transplantation are available to patients,increasing their chances of survival and improving their quality of life.Unfortunately,most patients are diagnosed with late stage HCC where only palliative treatment is available.Therefore,biomarkers which could detect HCC early with a high degree of sensitivity and specificity,may play a crucial role in the diagnosis and management of the disease.This review will aim to provide an overview of the different biomarkers of HCC comprising those used in the diagnosis of HCC in at risk populations,as well as others with potential for prognosis,risk predisposition and prediction of response to therapeutic intervention. | Gurjot Singh Eric M Yoshida Sahaj Rathi Vladimir Marquez Peter Kim Siegfried R Erb Baljinder S Salh | 2020 | World Journal of Hepatology2020，12，9： | 1 |
| 9 | Genotypic succession of mutations of the hepatitis B virus polymerase associated with lamivudine resistance显示文摘 | Klaus S Gutfreund Mark Williams Rajan George Vincent G Bain Mang M Ma Eric M Yoshida Jean-Pierre Villeneuve Karl P Fischer David L.J Tyrrell | 2000 | Journal of Hepatology2000，，3： | 1 |
| 10 | Hepatitis C Infection Among Pregnant Women in British Columbia: Reported Prevalence and Critical Appraisal of Current Prenatal Screening Methods显示文摘 | Blasig Audrey Wagner Emily C Pi David Bigham Mark Remple Valencia P Craib Kevin J P Doyle Patrick Dobson Simon Yoshida Eric M Patrick David Krajden Mel Money Deborah M | 2011 | Canadian Journal of Public Health2011，，2： | 1 |
| 11 | Unusual case of drug-induced cholestasis due to glucosamine and chondroitin sulfate显示文摘Glucosamine(GS) and chondroitin sulfate(CS) are common over-the-counter(OTC) supplements used in the treatment of osteoarthritis. These medications are seemingly safe, but there are increasing reports of hepatotoxicity with these supplements. We reported a unique case of drug-induced cholestasis caused by GS and CS in a combination tablet. The etiology of the jaundice was overlooked despite extensive investigations over a three-month period. Unlike drug-induced hepatocellular injury, drug-induced cholestatic jaundice with GS and CS has only been reported twice before. This case emphasizes the importance of a complete medication history, especially OTC supplements, in the assessment of cholestasis. | Stephen Ip Rachel Jeong David F Schaeffer Eric M Yoshida | 2015 | World Journal of Hepatology2015，7，24： | 1 |
| 12 | Severe cholestasis due to adalimumab in a Crohn's disease patient显示文摘Elevation of liver biochemistry has been reported with anti-tumor necrosis factor agents, but overt liver failure rarely reported. Autoimmune hepatitis has been more commonly reported with infliximab than adalimumab(ADA). Our case, however, describes the first reported case of ADA-associated severe cholestatic injury. A 39-year-old female with Crohn's disease developed severe jaundice after initiation of ADA. All serologic tests and imaging studies were normal. Liver biopsy showed prominent pericentral canalicular cholestasis,without features of steatosis or sclerosing cholangitis,consistent with drug-induced cholestasis. The serum total bilirubin peaked at 280 μmol/L, and improvement was seen after 5 wk with eventual normalization of liver enzymes at 10 wk. Our case describes the first reported case of ADA-associated severe cholestatic liver disease and the first histopathologic examination of this adverse drug effect. Clinicians need to be aware of this potential drug-induced liver injury when prescribing this commonly used biologic medication. | Edward Kim Brian Bressler David F Schaeffer Eric M Yoshida | 2013 | World Journal of Hepatology2013，5，10： | 1 |
| 13 | Retinal vein thrombosis associated with pegylated-interferon and ribavirin combination therapy for chronic hepatitis C显示文摘一估计世界范围的 3 亿个人在加拿大与一般人口的 0.8%-1.0% 的流行受不了长期的丙肝。证据的一个增加的水池存在为丙肝支持 pegylated- 干扰素(pegIFN ) 和 ribavirin 联合治疗的使用。我们与长期的丙肝(遗传型 2b ) 报导北美的土著的降下的 49 年的老男性。活体检视证实他与左眼疼痛的 2-wk 历史有肝硬化并且减少视敏度。他在 pegIFN-alpha 2a 和 ribavirin 联合治疗的 24 wk 中的 16 个以后得了网膜的静脉血栓。他是着急地指了一位网膜的专家并且与 non-ischemic 诊断了左眼的中央网膜的静脉吸藏。PegIFN 和 ribavirin 联合治疗被中止, HCV RNA 在处理的 16 wk 以后是无法发现的。Hematologic 调查表明病人是有温和地减少的蛋白质 C 活动的第五因子 Leiden 异质接合体。我们的病人有很多个亢奋的可凝结的风险因素,包括将很可能独自仍然保持临床上沉默的第五因子 Leiden 杂合现象,肝硬化,和丙肝。我们推测在 pegIFN 治疗的背景,这些冒因素的风险,这可以联合并且引起网膜的静脉血栓。 | Iman Zandieh Mohamed Adenwalla Cindy Cheong-Lee Patrick E Ma Eric M Yoshida | 2006 | World Journal of Gastroenterology2006，12，30： | 0 |
| 14 | Autoimmune liver disease and the Canadian First Nations Aboriginal Communities of British Columbia's Pacific Northwest显示文摘Primary biliary cirrhosis (PBC) is a well-known but uncommon chronic liver disease that is presumed to be of autoimmune etiology. Recently, investigations in British Columbia (BC), a province of Canada situated along the Pacific North-West of North America, have suggested that PBC is not a rare disease amongst BC's Aboriginal (i.e. First Nations) communities. Geographically, BC is adjacent to South East Alaska, an American state that has also reported an increased prevalence of PBC amongst its Aboriginal communities. In this article, the medical evidence supporting a hypothesis of increased risk of PBC amongst BC's First Nations communities is reviewed. Evidence suggesting that autoimmune hepatitis is also more likely amongst BC's First Nations communities is also presented. | Eric M Yoshida Mark Riley Laura T Arbour | 2006 | World Journal of Gastroenterology2006，12，23： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员